NORD comments to CMS regarding proposed changes to price reporting requirements under the Medicaid Drug Rebate Program.
Published: Jul 21, 2020
Tagged in: Access to Affordable Medicines, Medicare, Medicaid, and Private Health Insurance Coverage
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD comments to CMS regarding proposed changes to price reporting requirements under the Medicaid Drug Rebate Program.
Published: Jul 21, 2020
Tagged in: Access to Affordable Medicines, Medicare, Medicaid, and Private Health Insurance Coverage
Federal
Published: Oct 18, 2019
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
Coalition principles regarding the uptake of biosimilars
Published: Sep 1, 2019
Tagged in: Biosimilars, Access to Affordable Medicines
MAPRx letter to the Senate Committee on Finance regarding its drug pricing legislative package
Published: Jul 25, 2019
Tagged in: Access to Affordable Medicines, Federal Drug Pricing Legislation in the 116th Congress
NORD letter to the Senate Committee on Finance regarding its drug pricing legislative package
Published: Jul 24, 2019
Tagged in: Access to Affordable Medicines, Federal Drug Pricing Legislation in the 116th Congress
Coalition letter to Congress in support of a provision to increase the uptake of biosimilars
Published: Jul 3, 2019
Tagged in: Biosimilars, Access to Affordable Medicines